Shire’s SHP626 (Volixibat) Receives FDA Fast Track Designation for an Investigational Treatment for Adults who have Nonalcoholic Steatohepatitis (NASH) with Liver Fibrosis July 29, 2016 Lexington,... Monday HCV News Ticker- Hepatitis C: Coffee,...